Tiziana Life Sciences (TLSA) Projected to Post Earnings on Friday

Posted by Stanley Muller on Sep 17th, 2026

Tiziana Life Sciences (NASDAQ:TLSA – Get Free Report) is projected to announce its results before the market opens on Friday, September 18th. Analysts expect the company to announce earnings of ($0.0783) per share for the quarter.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ TLSA opened at $0.77 on Thursday. The firm’s 50-day simple moving average is $1.03 and its 200 day simple moving average is $1.21. Tiziana Life Sciences has a fifty-two week low of $0.76 and a fifty-two week high of $2.35.

Wall Street Analyst Weigh In

A number of analysts have commented on TLSA shares. Zacks Research upgraded shares of Tiziana Life Sciences to a “hold” rating in a research report on Tuesday, July 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tiziana Life Sciences in a report on Wednesday, August 26th. Finally, BTIG Research began coverage on shares of Tiziana Life Sciences in a research note on Thursday, September 3rd. They set a “buy” rating on the stock. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

View Our Latest Report on TLSA

Insider Buying and Selling at Tiziana Life Sciences

In related news, CEO Ivor Elrifi bought 237,616 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00. Following the acquisition, the chief executive officer directly owned 4,793,684 shares of the company’s stock, valued at $4,793,684. The trade was a 5.22% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Over the last three months, insiders acquired 988,423 shares of company stock worth $985,909. Company insiders own 39.82% of the company’s stock.

Tiziana Life Sciences Company Profile

(Get Free Report)

Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biotechnology company developing therapeutics for neuroinflammatory and autoimmune diseases. The company’s lead product candidate is foralumab, a fully human monoclonal antibody that targets the CD3 receptor on T cells and is being developed in an intranasal formulation designed to modulate immune activity.

Tiziana has evaluated foralumab in clinical research involving non-active secondary progressive multiple sclerosis and has also investigated its potential in conditions involving neuroinflammation, including Alzheimer’s disease.